Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Raw Materials: 2015-2024

Historic Raw Materials for Amphastar Pharmaceuticals (AMPH) over the last 10 years, with Dec 2024 value amounting to $81.5 million.

  • Amphastar Pharmaceuticals' Raw Materials rose 74.70% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.8 million, marking a year-over-year increase of 74.70%. This contributed to the annual value of $81.5 million for FY2024, which is 62.76% up from last year.
  • Amphastar Pharmaceuticals' Raw Materials amounted to $81.5 million in FY2024, which was up 62.76% from $50.1 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Raw Materials' 5-year high stood at $81.5 million during FY2024, with a 5-year trough of $41.9 million in FY2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Raw Materials had a median value of $50.1 million in 2023 and averaged $59.7 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Raw Materials declined by 20.57% in 2020, and later skyrocketed by 62.76% in 2024.
  • Amphastar Pharmaceuticals' Raw Materials (Yearly) stood at $47.1 million in 2020, then dropped by 11.05% to $41.9 million in 2021, then rose by 13.75% to $47.6 million in 2022, then climbed by 5.20% to $50.1 million in 2023, then skyrocketed by 62.76% to $81.5 million in 2024.